Aclaris Therapeutics, Inc.
ACRS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001557746
No open-market purchases or sales by Aclaris Therapeutics, Inc. insiders were filed in the last 90 days; 148 institutions reported holding it in 13F filings for Q2 2026, worth $630.0M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Aclaris Therapeutics, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 138
- +5 vs. Q2 2023
- Shares held
- 70.0M
- −1.12M (−1.6%) vs. Q2 2023
- Total value
- $480.0M
- −$257.2M (−34.9%) vs. Q2 2023
- New holders
- 20
- 61 more added
- Sold out
- 15
- 34 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ACRS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 148 | $630.0M |
| Q1 2026 | 136 | $409.4M |
| Q4 2025 | 122 | $252.1M |
| Q3 2025 | 103 | $162.8M |
| Q2 2025 | 96 | $130.4M |
| Q1 2025 | 109 | $143.8M |
| Q4 2024 | 98 | $217.0M |
| Q3 2024 | 81 | $58.5M |
| Q2 2024 | 98 | $58.1M |
| Q1 2024 | 98 | $67.5M |
| Q4 2023 | 107 | $61.4M |
| Q3 2023 | 138 | $480.0M |
| Q2 2023 | 133 | $737.2M |
| Q1 2023 | 149 | $579.3M |
| Q4 2022 | 128 | $1.04B |
| Q3 2022 | 127 | $1.00B |
| Q2 2022 | 115 | $883.3M |
| Q1 2022 | 110 | $1.02B |
| Q4 2021 | 133 | $814.9M |
| Q3 2021 | 126 | $1.02B |
| Q2 2021 | 128 | $983.4M |
| Q1 2021 | 97 | $1.14B |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Aclaris Therapeutics, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Dimensional Fund Advisors LP | 261,733 | $1.79M | 0.00% | +161,276+160.5% | Added |
| Frazier Life Sciences Management, L.P. | 264,377 | $1.81M | 0.12% | 00.0% | Unchanged |
| Schonfeld Strategic Advisors LLC | 269,746 | $1.85M | 0.02% | −184,665−40.6% | Reduced |
| Goldman Sachs Group Inc | 272,821 | $1.87M | 0.00% | −116,965−30.0% | Reduced |
| Verition Fund Management LLC | 299,685 | $2.05M | 0.03% | −351,242−54.0% | Reduced |
| HighTower Advisors, LLC | 369,802 | $2.53M | 0.00% | −10,000−2.6% | Reduced |
| JPMorgan Chase & Co | 400,321 | $2.74M | 0.00% | −26,638−6.2% | Reduced |
| Altium Capital Management LP | 403,000 | $2.76M | 1.60% | +403,000 | New |
| Aisling Capital Management LP | 434,455 | $2.98M | 1.23% | 00.0% | Unchanged |
| Lord, Abbett & Co. LLC | 453,954 | $3.11M | 0.01% | +55,602+14.0% | Added |
| Nuveen Asset Management, LLC | 460,313 | $3.15M | 0.00% | +258,896+128.5% | Added |
| Charles Schwab Investment Management Inc | 463,234 | $3.17M | 0.00% | +18,973+4.3% | Added |
| Renaissance Technologies LLC | 647,652 | $4.44M | 0.01% | −321,900−33.2% | Reduced |
| Northern Trust Corp | 659,371 | $4.52M | 0.00% | +9,444+1.5% | Added |
| FMR LLC | 661,300 | $4.53M | 0.00% | −86,765−11.6% | Reduced |
| Point72 Asset Management, L.P. | 662,529 | $4.54M | 0.02% | −1,073,971−61.8% | Reduced |
| Assenagon Asset Management S.A. | 687,135 | $4.71M | 0.02% | +50,306+7.9% | Added |
| Samsara BioCapital, LLC | 696,171 | $4.77M | 1.46% | 00.0% | Unchanged |
| Vivo Capital, LLC | 898,631 | $6.16M | 0.76% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 1,000,000 | $6.85M | 0.02% | 00.0% | Unchanged |
| VR Adviser, LLC | 1,040,754 | $7.13M | 0.75% | 00.0% | Unchanged |
| Foresite Capital Management V, LLC | 1,258,243 | $8.62M | 13.75% | 00.0% | Unchanged |
| Blackstone Group Inc. | 1,261,425 | $8.64M | 0.04% | +1,248,392+9,578.7% | Added |
| Geode Capital Management, LLC | 1,337,082 | $9.16M | 0.00% | +99,673+8.1% | Added |
| Samlyn Capital, LLC | 1,463,074 | $10.0M | 0.18% | +119,005+8.9% | Added |
| State Street Corp | 1,562,508 | $10.7M | 0.00% | +110,524+7.6% | Added |
| Great Point Partners LLC | 1,691,768 | $11.6M | 2.18% | −249,813−12.9% | Reduced |
| Morgan Stanley | 1,698,391 | $11.6M | 0.00% | +63,576+3.9% | Added |
| Millennium Management LLC | 1,967,980 | $13.5M | 0.01% | +1,140,896+137.9% | Added |
| Foresite Capital Management IV, LLC | 2,808,034 | $19.2M | 10.68% | 00.0% | Unchanged |
| Citadel Advisors LLC | 3,357,240 | $23.0M | 0.02% | +744,166+28.5% | Added |
| Vanguard Group Inc | 3,363,046 | $23.0M | 0.00% | +33,482+1.0% | Added |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23.3M | 2.60% | 00.0% | Unchanged |
| Rock Springs Capital Management LP | 3,960,449 | $27.1M | 0.73% | −1,4000.0% | Reduced |
| Ra Capital Management, L.P. | 4,398,453 | $30.1M | 0.59% | 00.0% | Unchanged |
| BlackRock Inc. | 5,607,890 | $38.4M | 0.00% | +13,717+0.2% | Added |
| Wellington Management Group LLP | 6,979,844 | $47.8M | 0.01% | −658,024−8.6% | Reduced |
| BVF Inc | 7,064,736 | $48.4M | 1.30% | +3,703,795+110.2% | Added |
| Braidwell LP | 0 | $0 | 0.00% | −2,901,194−100.0% | Sold out |
| Holocene Advisors, LP | 0 | $0 | 0.00% | −1,485,056−100.0% | Sold out |
| TCG Crossover Management, LLC | 0 | $0 | 0.00% | −529,839−100.0% | Sold out |
| Logos Global Management LP | 0 | $0 | 0.00% | −525,000−100.0% | Sold out |
| Silverarc Capital Management, LLC | 0 | $0 | 0.00% | −219,229−100.0% | Sold out |
| Ikarian Capital, LLC | 0 | $0 | 0.00% | −200,163−100.0% | Sold out |
| Soleus Capital Management, L.P. | 0 | $0 | 0.00% | −151,000−100.0% | Sold out |
| HighVista Strategies LLC | 0 | $0 | 0.00% | −86,103−100.0% | Sold out |
| Los Angeles Capital Management LLC | 0 | $0 | 0.00% | −75,006−100.0% | Sold out |
| Westwood Holdings Group Inc. | 0 | $0 | 0.00% | −51,023−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −40,973−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −30,423−100.0% | Sold out |
| The PNC Financial Services Group, Inc. | 0 | $0 | 0.00% | −912−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −754−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −500−100.0% | Sold out |